Targeted integration into stem cells
| Title: | Targeted integration into stem cells |
|---|---|
| Patent Number: | 9,834,787 |
| Publication Date: | December 05, 2017 |
| Appl. No: | 12/798749 |
| Application Filed: | April 08, 2010 |
| Abstract: | Disclosed herein are methods and compositions for targeted integration of sequences of interest such as lineage-specific or cell fate reporter constructs or protein encoding sequences into stem cells. |
| Inventors: | Gregory, Philip D. (Orinda, CA); Hockemeyer, Dirk (Cambridge, MA, US); Holmes, Michael C. (Oakland, CA, US); Jaenisch, Rudolf (Cambridge, MA, US); Soldner, Frank (Cambridge, MA, US); Urnov, Fyodor (Point Richmond, CA, US); Yao, Shuyuan (San Diego, CA, US) |
| Assignees: | Sangamo Therapeutics, Inc. (Richmond, CA, US) |
| Claim: | 1. An isolated pluripotent or multipotent stem cell comprising a transgene, wherein the transgene is integrated into an endogenous PITX3 or Factor IX gene of the stem cell using a pair of zinc finger nucleases that bind to and cleave the endogenous PITX3 or Factor IX gene, wherein the pair of zinc finger nucleases bind to paired target sites of SEQ ID NO:47 and SEQ ID NO:48 of the PITX3 gene, or paired target sites of SEQ ID NO:49 and SEQ ID NO:50 of the PITX3 gene, or to paired target sites of SEQ ID NO:51 and SEQ ID NO:56 of the Factor IX gene, and further wherein the pair of zinc finger nucleases cleaves the PITX3 or Factor IX gene within or between the paired target sites such that the transgene is integrated into the PITX3 or Factor IX gene. |
| Claim: | 2. The isolated stem cell of claim 1 , wherein the stem cell is selected from the group consisting of a hematopoietic stem cell, a mesenchymal stem cell, an embryonic stem cell, a neuronal stem cell, a muscle stem cell, a liver stem cell, a skin stem cell, and an induced pluripotent stem cell. |
| Claim: | 3. The isolated stem cell of claim 1 , wherein the stem cell is a mammalian stem cell. |
| Claim: | 4. The isolated stem cell of claim 3 , wherein the stem cell is a human induced pluripotent stem cell (hiPSC). |
| Claim: | 5. The isolated stem cell of claim 1 , wherein the transgene is flanked by recombinase sites. |
| Claim: | 6. The isolated stem cell of claim 1 , further comprising a sequence encoding a reporter construct. |
| Claim: | 7. A stem cell according to claim 1 , wherein the isolated transgene comprises a sequence encoding a lineage-specific or cell fate marker as shown in Table 1. |
| Patent References Cited: | 5356802 October 1994 Chandrasegaran 5420032 May 1995 Marshall et al. 5436150 July 1995 Chandrasegaran 5487994 January 1996 Chandrasegaran 5639618 June 1997 Gay 5789538 August 1998 Rebar et al. 5925523 July 1999 Dove et al. 5928638 July 1999 Uchida et al. 6007988 December 1999 Choo et al. 6013453 January 2000 Choo et al. 6090618 July 2000 Parmacek et al. 6140081 October 2000 Barbas 6140466 October 2000 Barbas et al. 6200759 March 2001 Dove et al. 6242568 June 2001 Barbas et al. 6410248 June 2002 Greisman et al. 6453242 September 2002 Eisenberg et al. 6479626 November 2002 Kim et al. 6503717 January 2003 Case et al. 6534261 March 2003 Cox et al. 6599692 July 2003 Case et al. 6607882 August 2003 Cox et al. 6689558 February 2004 Case 6824978 November 2004 Cox et al. 6833252 December 2004 Dujon et al. 6903185 June 2005 Kim et al. 6933113 August 2005 Case et al. 6979539 December 2005 Cox et al. 7013219 March 2006 Case et al. 7153949 December 2006 Kim et al. 7163824 January 2007 Cox et al. 7951925 May 2011 Ando et al. 2002/0114788 August 2002 Isacson et al. 2003/0003581 January 2003 Economides et al. 2003/0232410 December 2003 Liljedahl et al. 2004/0096432 May 2004 Fleischmann et al. 2004/0219563 November 2004 West et al. 2005/0026157 February 2005 Baltimore et al. 2005/0064474 March 2005 Urnov et al. 2005/0208489 September 2005 Carroll et al. 2006/0188987 August 2006 Guschan et al. 2006/0240556 October 2006 Cibelli 2007/0134796 June 2007 Holmes et al. 2007/0218528 September 2007 Miller et al. 2008/0131962 June 2008 Miller 2008/0159996 July 2008 Ando et al. 2008/0216185 September 2008 Chesnut et al. 2008/0299580 December 2008 DeKelver et al. 2009/0117617 May 2009 Holmes et al. 2009/0305419 December 2009 Miller et al. 2338237 December 1999 WO 95/19431 July 1995 WO 96/06166 February 1996 WO 98/37186 August 1998 WO 98/53057 November 1998 WO 98/53058 November 1998 WO 98/53059 November 1998 WO 98/53060 November 1998 WO 98/54311 December 1998 WO 00/27878 May 2000 WO 01/60970 August 2001 WO 01/88197 November 2001 WO 02/16536 February 2002 02/064748 August 2002 WO 02/077227 October 2002 WO 02/099084 December 2002 WO 03/016496 February 2003 2006/076374 July 2006 2006/127809 November 2006 WO 2007/014275 January 2007 WO 2008/089396 July 2008 WO 2008/126083 October 2008 WO 2008/133938 November 2008 |
| Other References: | Faust et al., Blood, 96(2): 719-726, 2000. cited by examiner Gupta et al., Mol. And Cell. Biol., 18(12): 7243-4258, 1998. cited by examiner Takahashi et al., Cell, 131: 12-12, Nov. 30, 2007. cited by examiner Abuin et al., Molecular and Cellular Biology, 16(4): 1851-1856, 1996. cited by examiner Wu et al., Cell Molecular Life Sci., 64(200: 2933-2944, 2007. cited by examiner Davis et al., Nature Protocols, 3(10): 1550-1558, 2008. cited by examiner Qian et al., Stem Cells, 32(5): 1230-1238, 2014. cited by examiner DeKelver et al., Genome Research, 20: 1133-1142. cited by examiner Hockemeyer et al., Nature Biotechnology, 27(9): 851-857, Sep. 2009. cited by examiner Liu et al., PLoS One, 7(5): e37071, pp. 1-8, 2012. cited by examiner Argast, et al., “I-PPOI and I-CREI Homing Site Sequence Degeneracy Determined by Random Mutagenesis and Sequential in Vitro Enrichment,” J. Mol. Biol. 280:345-353 (1998). cited by applicant Ashworth, et al., “Computational Redesign of Endonuclease DNA Binding and Cleavage Specificity,” Nature 441:656-659 (2006). cited by applicant Beerli, et al., “Engineering Polydactyl Zinc-Finger Transcription Factors,” Nature Biotechnology 20:135-141 (2002). cited by applicant Belfort, et al., “Homing Endonucleases: Keeping the House in Order,” Nucleic Acids Research 25:3379-3388 (1997). cited by applicant Bitinate, et al., “Foki Dimerization Is Required for DNA Cleavage,” PNAS USA 95:10570-10575 (1998). cited by applicant Boch, et al., “Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors,” Science 326:1509-1512 (2009). cited by applicant Brambrink et al., “Sequential Expression of Pluripotency Markers During Direct Reprogramming of Mouse Somatic Cells,” Cell Stem Cell 2:151-159 (2008). cited by applicant Chevalier, et al., “Design, Activity, and Structure of a Highly Specific Artificial Endonuclease,” Molecular Cell 10:895-905 (2002). cited by applicant Chisaka, et al., “Regionally Restricted Developmental Defects Resulting From Targeted Disruption of the Mouse Homeobox Gene HOX-1.5,” Nature 350:473-479 (1991). cited by applicant Choo, et al., “Advances in Zinc Finger Engineering,” Curr. Opin. Struct. Biol. 10:411-416 (2000). cited by applicant Creaser, et al., “Comparative and Functional Analysis of the AP2 Promoter Indicates That Conserved Octamer and Initiator Elements Are Critical for Activity,” Nucleic Acids Res 24:2597-2606 (1996). cited by applicant DePalma, et al., “Promoter Trapping Reveals Significant Differences in Integration Site Selection Between MLV and HIV Vectors in Primary Hematopoietic Cells,” Blood 105:2307-2315 (2005). cited by applicant Dimos, et al., “Induced Pluripotent Stem Cells Generated From Patients With ALS Can Be Differentiated Into Motor Neurons,” Science 321:1218-1221 (2008). cited by applicant Donovan, et al., “The End of the Beginning for Pluripotent Stem Cells,” Nature 414:92-97 (2001). cited by applicant Dujon, et al., “Mobile Introns: Definition of Terms and Recommended Nomenclature,” Gene 82:115-118 (1989). cited by applicant Eliopoulos, et al., “Bone Marrow-Derived Mesenchymal Stromal Cells (MSCS) as Efficient in Vivo Cellular Vehicles for Plasma Soluble Protein Delivery,” Blood Cells, Molecules and Diseases 40:263-264 (2008). cited by applicant Epinat, et al., “A Novel Engineered Meganuclease Induces Homologous Recombination in Yeast and Mammalian Cells,” Nucleic Acids Research 31:2952-2962 (2003). cited by applicant Gimble, et al., “Substrate Recognition and Induced DNA Distortion by the PI-SCEI Endonuclease, an Enzyme Generated by Protein Splicing,” J. Mol. Biol. 263:163-180 (1996). cited by applicant Hockemeyer, et al., “A Drug-Inducible System for Direct Reprogramming of Human Somatic Cells to Pluripotency,” Cell Stem Cell 3:346-353 (2008). cited by applicant Isalan et al., “A Rapid, Generally Applicable Method to Engineer Zinc Fingers Illustrated by Targeting the HIV-1 Promoter,” Nat Biotechnol 19:656-660 (2001). cited by applicant Isman, et al., “Adenovirus-Based Targeting in Myoblasts Is Hampered by Nonhomologous Vector Integration,” Human Gene Therapy 19:1000-1008 (2008). cited by applicant Jasin, et al., “Genetic Manipulation of Genomes With Rare-Cutting Endonucleases,” Trends Genet 12:224-228 (1996). cited by applicant Kim, et al., “Chimeric Restriction Endonuclease,” PNAS USA 91:883-887 (1994). cited by applicant Kim, et al., “Insertion and Deletion Mutants of FOKI Restriction Endonuclease,” J. Biol. Chem. 269:31978-31981 (1994). cited by applicant Levasseur, et al., “OCT4 Dependence of Chromatin Structure Within the Extended NANOG Locus in ES Cells,” Genes Dev 22:575-580 (2008). cited by applicant Li, et al., “Functional Domains in FOK I Restriction Endonuclease,” PNAS USA 89:4275-4279 (1992). cited by applicant Li, et al., “Alteration of the Cleavage Distance of FOK I Restriction Endonuclease by Insertion Mutagenesis,” PNAS USA 90:2764-2768 (1993). cited by applicant Lovell-Badge, et al., “The Future for Stem Cell Research,” Nature 414:88-91 (2001). cited by applicant Miller, et al., “An Improved Zinc-Finger Nuclease Architecture for Highly Specific Genome Editing,” Nature Biotech 25:778-785 (2007). cited by applicant Moscou, et al., “A Simple Cipher Governs DNA Recognition by TAL Effectors,” Science 326:1501 (2009). cited by applicant Nakagawa, et al., “Generation of Induced Pluripotent Stem Cells Without MYC From Mouse and Human Fibroblasts,” Nat Biotech 26:101-106 (2008). cited by applicant Pabo, et al., “Design and Selection of Novel CYS2—HIS2 Zinc Finger Proteins,” Ann. Rev. Biochem. 70:313-340 (2001). cited by applicant Paques, et al., “Meganucleases and DNA Double-Strand Break-Induced Recombination: Perspectives for Gene Therapy,” Current Gene Therapy 7:49-66 (2007). cited by applicant Pedersen, et al., “Studies of in Vitro Differentiation With Embryonic Stem Cells,” Reproduc Fertil Dev 6:543-552 (1994). cited by applicant Perez, et al., “Establishment of HIV-1 Resistance in CD4+ T Cells by Genome Editing Using Zinc-Finger Nucleases,” Nature Biotechnology 26:808-816 (2008). cited by applicant Perler, et al., “Protein Splicing Elements: Inteins and Exteins a Definition of Terms and Recommended Nomenclature,” Nucleic Acids Research 22:1125-1127 (1994). cited by applicant Porteus, et al., “Isolation and Characterization of a Novel CDNA Clone Encoding a Homeodomain That Is Developmentally Regulated in the Ventral Forebrain,” Neuron 7:221-229 (1991). cited by applicant Price, et al., “A Mouse Gene Related to Distal-Less Shows a Restricted Expression in the Developing Forebrain,” Nature 351:748-751 (1991). cited by applicant Robertson, “Derivation and Maintenance of Embryonic Stem Cell Cultures,” Meth Mol Biol 75:173-184 (1997). cited by applicant Roelink, et al., “Expression of Two Members of the WNT Family During Mouse Development-Restricted Temporal and Spatial Patterns in the Developing Neural Tube,” Genes Dev 5:381-388 (1991). cited by applicant Segal, et al., “Custom DNA-Binding Proteins Come of Age: Polydactyl Zinc-Finger Proteins,” Curr. Opin. Biotechnol. 12:632-637 (2001). cited by applicant Simeone, et al., “Two Vertebrate Homeobox Genes Related to the Drosophila Empty Spiracles Gene Are Expressed in the Embryonic Cerebral Cortex,” EMBO J 11:2541-2550 (1992). cited by applicant Smith, et al., “Robust, Persistent Transgene Expression in Human Embryonic Stem Cells Is Achieved With AAVS1-Targeted Integration,” Stem Cells 26:496-506 (2008). cited by applicant Soldner, et al., “Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors,” Cell 36:964-977 (2009). cited by applicant Strathdee, et al., “Expression of Transgenes Targeted to the GT(ROSA)26SOR Locus Is Orientation Dependent,” Plos ONE 1(e4):1-9 (2006). cited by applicant Urnov, et al., “Highly Efficient Endogenous Human Gene Correction Using Designed Zinc-Finger Nucleases,” Nature 435:646-651 (2005). cited by applicant Bruce, S. J. et al., “In vitro differentiation of murine embryonic stem cells toward a real lineage”, Differentiation, vol. 75, No. 5, Jun. 1, 2007 (Jun. 1, 2007), pp. 337-349. cited by applicant Lombardo, et al., “Gene Editing in Human Stem Cells Using Zinc Finger Nucleases and Integrase-Defective Lentiviral Vector Delivery,” Nature Biotechnology 25(11):1298-1306 (2007). cited by applicant Porteus, et al., “Gene Targeting Using Zinc Finger Nucleases,” Nature Biotechnology 23(8):967-973 (2005). cited by applicant Moehle, et al., “Targeted Gene Addition Into a Specified Location in the Human Genome Using Designed Zinc Finger Nucleases,” PNAS USA 104(9):3055-3060 (2007). cited by applicant Zhao, et al., “Generation of Embryonic Stem Cells and Transgenic Mice Expressing Green Fluorescence Protein in Midbrain Dopaminergic Neurons,” European Journal of Neuroscience, vol. 19, pp. 1133-1140 (2004). cited by applicant |
| Primary Examiner: | Ton, Thaian N |
| Attorney, Agent or Firm: | Pasternak Patent Law Abrahamson, Susan |
| Accession Number: | edspgr.09834787 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|